Those who are currently looking into opportunities in the healthcare sector could do well to consider having a look at the Halberd Corporation (OTCMKTS:HALB) stock.
While it is true that there has been no news about the company this morning, it was in fact in the news back on Wednesday and it is something that is worth looking into. The company announced that it was moving into the next level of research after it had been successful in the elimination of the 10 top antigens which are related to neurodegenerative diseases.
The company announced on March 16 that it had added the famed educator and infectious disease specialist Ravi VenkataDurvasula to its consultants and technical expert team. It was a major new announcement from the company considering the fact that Durvasula is going to be working on deploying the company’s patented extracorporeal disease antigen elimination process with regards to infectious diseases in his new capacity.
This marks an important move for Halberd as it moves into the field of infectious diseases after having worked on neurodegenerative diseases. It could now be a good idea for investors to add the Halberd stock to their watch lists and watch for further developments.
William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “We are extremely pleased to have Dr. Ravi join our team, as we continually add to our tremendous team of experts. He will be an invaluable asset as we expand the application of our patented extracorporeal treatment of diseases as we prepare for animal testing. The fact that Halberd has been blessed with such talented individuals is a testimony to the strength of our intellectual properties and the dedication of our staff. Application of our technology to curing a range of diseases will be our goal in the foreseeable future.”
